Dolutegravir vs Nivolumab

## Dolutegravir vs Nivolumab: Overview

This comparison examines the pharmacological differences between **Dolutegravir** and **Nivolumab**.

## Mechanism of Action

**Nivolumab**: Fully human anti-PD-1 IgG4 monoclonal antibody restoring T-cell anti-tumor activity.

## Pharmacokinetics

**Half-life**: Dolutegravir — N/A; Nivolumab — 27 days.

## Chemical Properties

**Type**: Dolutegravir — Small molecule; Nivolumab — Antibody.